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Chlamydia pneumoniae Stimulates IFN- Synthesis through
MyD88-Dependent, TLR2- and TLR4-Independent Induction
of IL-18 Release1
Mihai G. Netea,2*‡ Bart Jan Kullberg,*‡ Liesbeth E. H. Jacobs,*‡ Trees J. G. Verver-Jansen,*‡
Johanna van der Ven-Jongekrijg,*‡ Jochem M. D. Galama,†‡ Anton F. H. Stalenhoef,*
Charles A. Dinarello,§ and Jos W. M. Van der Meer*
Recent studies suggest that inflammation plays a central role in the pathogenesis of atherosclerosis, and IFN- is a prominent
proinflammatory mediator in this context. However, it is unclear what stimuli are responsible for initial stimulation of IFN-
synthesis in the vessel wall. In the present study, we demonstrate that Chlamydia pneumoniae is an important stimulus for IFN-
synthesis, and this production depends on release of endogenous IL-18, IL-12, and IL-1, but not of TNF. The production of the
proinflammatory cytokines TNF and IL-1 from PBMC by sonicated C. pneumoniae was mediated through TLR2-dependent
pathways. In contrast, C. pneumoniae stimulated the production of IL-18 through MyD88-dependent, TLR2-, TLR4-, and CD14-
independent pathways, mediated by posttranscriptional mechanisms not involving de novo protein synthesis. In conclusion, C.
pneumoniae is a potent stimulus of IFN- production, in addition to the proinflammatory cytokines TNF and IL-1, which may
contribute to its proatherogenic effects. Most interestingly, C. pneumoniae is also a potent inducer of IL-18 production through
pathways independent of TLR2 and TLR4. The Journal of Immunology, 2004, 173: 1477–1482.
T here is increasing evidence that immune mechanisms playa central role in the pathogenesis of atherosclerosis, andproinflammatory cytokines are important mediators of
these processes. Recent studies have shown that especially IFN-
plays a central role in the development of atherosclerotic lesions.
IFN- mRNA and protein has been shown to be present in ath-
erosclerotic plaques (1), and administration of IFN- to apoE/
mice promotes atherosclerosis (2). Conversely, deficiency of the
IFN-R leads to a profound decrease in the atherosclerotic lesions
of apoE/ mice (3). The secretion of IFN- is promoted by proin-
flammatory mediators such as IL-18 and IL-12 released from the
monocytes and macrophages. Recent data put IL-18 in a central
role in the inflammatory processes leading to atherosclerosis, with
expression of IL-18 on macrophages and IL-18Rs on human vas-
cular endothelial cells, smooth muscle cells, and macrophages (4).
IL-18 signaling evokes actions implicated in the pathogenesis of
atherosclerosis, such as cytokine and chemokine induction and ad-
hesion molecule expression (4), and expression of IL-18 in the
human atherosclerotic plaques seems to correlate with plaque in-
stability (5).
It is not known what factors induce IFN- and IL-18 production
in the vessel wall. In recent years, infections caused by the obligate
intracellular Gram-negative bacterium Chlamydia pneumoniae
have been connected to coronary heart disease and atherosclerosis
(6, 7). C. pneumoniae has been detected in atheromatous lesions of
patients (8), and in recent animal studies infection with C. pneu-
moniae induced and accelerated atherosclerosis (9). There are sev-
eral mechanisms through which C. pneumoniae could induce ath-
erosclerosis, including production of proinflammatory cytokines
and chemokines (10), induction of adhesion molecules expression
(11), and transendothelial migration of inflammatory cells (12).
We hypothesized that an additional proatherogenic mechanism
triggered by C. pneumoniae is the stimulation of IL-18 and, sec-
ondarily, IFN- release.
Materials and Methods
Reagents
Escherichia coli LPS (serotype 055:B5), peptidoglycan, and cyclohexi-
mide were obtained from Sigma-Aldrich (St. Louis, MO). rIL-18 binding
protein (BP)3 (recombinant human IL-18BP expressed in Chinese hamster
ovary cells with carboxyl His6) was produced as previously described (13).
Recombinant human IL-1R agonist (IL-1ra) was a kind gift of Dr. D.
Tracey (Upjohn, Kalamazoo, MI). Recombinant human TNFBP (4 domain
p55 soluble TNFR) was kindly provided by Dr. C. Edwards (Amgen, Boul-
der, CO). The monoclonal mouse anti-human IL-12 Ab was purchased
from R&D Systems (Minneapolis, MN). The monoclonal anti-TLR4
HTA125 Ab was a kind gift of Dr. K. Miyake (Saga Medical School, Saga,
Japan). The monoclonal anti-TLR2 Ab was kindly provided by Dr. D.
Golenbock (Boston University, Boston, MA). The monoclonal anti-CD14
WT14 Ab was a kind gift of Dr. W. Tax (University Medical Center,
Nijmegen, The Netherlands). RPMI 1640 culture medium (Life Technol-
ogies, Grand Island, NY) was supplemented with 10 mM L-glutamine, 100
U/ml penicillin, and 100 g/ml streptomycin (Life Technologies). An ir-
relevant mouse anti-human IgG Ab was used as a negative control, and did
not influence cytokine release.
Animals
Specific pathogen-free TLR4-defective (ScCr) mice (14) and age- and
weight-matched wild-type (C57BL/10) mice (20–25 g, 6–8 wk old) were
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used for the experiments. TLR2-deficient (TLR2/) and MyD88-deficient
(MyD88/) mice on a C57BL/6J background were kindly provided by
Dr. S. Akira (Research Institute of Microbial Diseases, Osaka University,
Osaka, Japan), and the control C57BL/6J mice (TLR2/ controls) were
purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were fed
sterilized laboratory chow (Hope Farms, Woerden, The Netherlands) and
water, ad libitum.
C. pneumoniae
C. pneumoniae TW-183 was grown in Hep2 cells, cultured in HEPES-
buffered MEM containing 10% FCS, 0.5% (w/v) glucose and 0.5% (w/v)
cycloheximide (Flow Laboratories, Irvine, U.K.). After 48, 72, and 96 h,
the supernatant containing elementary bodies released from the cells was
collected and pooled. The cell debris was separated by low speed centrif-
ugation (10 min, 500 g). The infectivity of the Chlamydia-containing su-
pernatants (inclusion-forming units (IFU)) was further tested in Hep2 cells
and adjusted to 105 IFU/ml. As a control, supernatants from cultures of
uninfected Hep2 cells were collected and prepared in a similar manner as
described above. C. pneumoniae was killed by sonication for 10 min, on ice
(Bransonic 2200; Branson, Shelton, CT). Sonicated C. pneumoniae was
used in all experiments, if not otherwise indicated. The same procedure
was followed for the conditioned medium obtained from uninfected Hep2
cells. Heat-killed (30 min, 100°C) C. pneumoniae, Candida albicans strain
UC820, and a clinical isolate of Staphylococcus aureus were used in some
of the experiments, as indicated.
In a control experiment, the supernatants containing Chlamydia were
centrifuged, the cell pellets containing the microorganisms were washed
three times in sterile RPMI 1640 and resuspended in culture medium. No
differences in terms of cytokine production were detected between the su-
pernatants containing Chlamydia and the repurified preparations (data not
shown).
Stimulation of cytokine production in human PBMC
Venous blood was drawn from the cubital vein of healthy volunteers into
three 10-ml EDTA tubes (Monoject, s-Hertogenbosch, The Netherlands).
The PBMC fraction was obtained by density centrifugation of blood di-
luted 1/1 in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech,
Uppsala, Sweden). PBMC were washed twice in saline and suspended in
culture medium (RPMI 1640 Dutch modification) supplemented with gen-
tamicin 10 g/ml, L-glutamine 10 mM, and pyruvate 10 mM. The cells
were counted in a Coulter counter (Coulter Electronics, Mijdrecht, The
Netherlands), and the number was adjusted to 5  106 cells/ml.
A of total of 5  105 PBMC in a 100-l volume were added to round-
bottom 96-well plates (Greiner Bioscience, Alphen a/d Rijn, The Nether-
lands), and incubated with either 100 l of conditioned medium from un-
infected Hep2 cells, sonicated C. pneumoniae (104 IFU/ml, unless
otherwise indicated), heat-killed C. albicans (107 microorganisms/ml),
heat-killed S. aureus (107 microorganisms/ml), LPS (10 ng/ml), or pepti-
doglycan (10 g/ml). In a pilot experiment, we have measured IL-18 con-
centrations after 1, 4, 8, and 24 h, and found that IL-18 reaches a plateau
after 8 h and remains unchanged at 24 h. Twenty-four-hour stimulation has
been chosen as the stimulation period for the rest of the experiments.
In blocking studies, the cytokine inhibitors IL-18BP (125 ng/ml), anti-
IL-12 (5 g/ml), IL-1ra (10 g/ml), and TNFBP (10 g/ml) were added to
the cells. These concentrations block the bioactivity of the respective cy-
tokines, as shown in separate experiments (data not shown). In additional
experiments aimed to assess the role of CD14 and TLRs for stimulation of
cytokines, PBMC were preincubated (1 h, 37°C) with the various mAbs
(anti-TLR4, anti-TLR2, or anti-CD14; 20 g/ml) before the stimulation
with C. pneumoniae. As a heparan sulfate-like glycosaminoglycan has
been shown to be a C. pneumoniae receptor on epithelial cells, the effect of
blocking this potential chlamydial receptor with 500 g/ml heparin was
investigated, as previously reported (15). To investigate the effects of de
novo protein synthesis on IL-18 release, PBMC were stimulated with C.
pneumoniae in the presence of 10 g/ml cycloheximide (16). In a separate
experiment, we have investigated the effect of IL-1 converting enzyme
(ICE) inhibition by a specific inhibitor (10 M Ac-Tyr-Val-Ala-Asp-chlo-
romethylketone; Bachem, Bubendorf, Switzerland) on the release of IL-18.
After 24 or 48 h of incubation at 37°C, the supernatants were collected and
stored at 70°C until assay.
Cytokine production by murine peritoneal macrophages
Resident peritoneal macrophages from either ScCr and C57BL/10 mice, or
TLR2/ and C57BL/6J mice, were harvested by injecting 4 ml of sterile
PBS containing 0.38% sodium citrate. After centrifugation and washing,
the cells were resuspended in RPMI 1640 containing 1 mM pyruvate, 2
mM L-glutamine, 100 g/ml gentamicin, and 2% fresh mouse plasma.
Cells were cultured in 96-well microtiter plates (Greiner Bioscience) at 1
105 cells/well, in a volume of 100 l. The cells were stimulated with 100
l of conditioned medium from uninfected Hep2 cells, or sonicated C.
pneumoniae (final concentration, 1  104 IFU/ml). After 24-h incubation
at 37°C, the supernatants were collected and stored at 70°C until cyto-
kine assays were performed.
Cytokine measurements
Human TNF- and IL-1 concentrations were determined by specific
RIAs, with a detection limit of 20 pg/ml. IFN- concentrations were mea-
sured by commercial ELISA (Pelikine Compact; Sanguin Laboratories,
Amsterdam, The Netherlands), according to the instructions of the manu-
facturer. Human and murine IL-18 levels were assessed by a commercial
ELISA kit (R&D Systems). The detection limit of the assay was 8 pg/ml.
Murine IL-1 and TNF- were determined by specific RIAs (detection
limit, 20 pg/ml), as previously described (17).
Statistical analysis
The human experiments were performed in triplicate in a total of seven
volunteers, and all data were pooled. The mouse experiments were per-
formed twice in five mice per group, and the data are presented as cumu-
lative results of all experiments performed. The differences between groups
were analyzed by Mann-Whitney U test, and, where appropriate, by
Kruskal-Wallis ANOVA test. The level of significance between groups
was set at p  0.05. The data are given as mean  SEM.
Results
C. pneumoniae stimulates IFN- production
Stimulation of human PBMC for 24 h with either live or sonicated
C. pneumoniae from a culture containing 104 IFU/ml resulted in
significant production of TNF and IL-1 (Fig. 1). In addition,
IFN- production was also induced by C. pneumoniae sonicates
when compared with conditioned medium from Hep2 cells (Fig.
1), although C. pneumoniae was less potent in the induction of
IFN- (240  20 pg/ml) compared with LPS (720  140 pg/ml),
C. albicans (1760  430 pg/ml), or S. aureus (5800  1230 pg/
ml). Conditioned medium from uninfected cultures induced small
but measurable IFN- in some donors. However, when PBMC
were stimulated with either live Chlamydia or chlamydial soni-
cates, a 4- to 14-fold-increase in IFN- occurred ( p  0.01). In
contrast, heat-killed C. pneumoniae induced only 10–25% of the
cytokine production stimulated by live microorganisms (Fig. 1).
Previous studies have demonstrated that mature IL-18 is re-
quired for the LPS-induced production of IFN-, even when IL-12
is present (18). To investigate the role of endogenous IL-18 for the
C. pneumoniae-induced IFN- synthesis, IL-18BP was added to
the PBMC cultures. IL-18BP reduced C. pneumoniae-induced
IFN- production by 57% ( p  0.03, Fig. 2). Addition of anti-
FIGURE 1. Stimulation of cytokine production by C. pneumoniae. Hu-
man PBMC were stimulated for 24 h with conditioned medium (f), live
(3), sonicated (u), or heat-killed (^) 104 IFU/ml C. pneumoniae. TNF
and IL-1 (after 24-h stimulation), or IFN- (after 48-h stimulation) con-
centrations were measured by RIA or ELISA. Donors, n  7; , p  0.01
when compared with stimulation by conditioned medium.
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IL-12 Abs or IL-1ra to the PBMC stimulated by Chlamydia re-
duced the production of IFN- by 42 ( p  0.05) and 65% ( p 
0.01), respectively (Fig. 2). In contrast, no significant effect of
TNFBP on C. pneumoniae-induced IFN- could be observed. TN-
FBP significantly decreased LPS-induced IL-8 release by 54%,
demonstrating that it is biologically active (data not shown). A
combination of IL-18BP and anti-IL-12 Abs reduced C. pneu-
moniae-induced IFN- production by 82% ( p  0.01, Fig. 2).
C. pneumoniae is a strong stimulus for IL-18 production
The marked inhibitory effect of IL-18BP on C. pneumoniae-in-
duced IFN- implies that Chlamydia is a potent stimulus of IL-18
production. Stimulation of PBMC with sonicated C. pneumoniae
resulted in a dose-dependent stimulation of IL-18 production (Fig.
3). C. pneumoniae appeared to be a more potent stimulus of IL-18
production than other stimuli, as shown by the maximal stimula-
tion index (vs conditioned medium) obtained with sonicated (200-
fold) or heat-killed (30-fold) Chlamydia, much higher than the
stimulation index obtained with LPS (5-fold), C. albicans (8-fold),
and S. aureus (5-fold) (Fig. 3).
Stimulation of cytokines by C. pneumoniae does not involve
TLR4 and CD14
Preincubation of human PBMC for 1 h with anti-TLR4 Abs did not
influence the stimulation of TNF, IL-1, and IL-18 by C. pneu-
moniae (Fig. 4A). As expected, the anti-TLR4 Abs significantly
down-regulated the production of TNF after stimulation by E. coli
LPS (85% inhibition, p  0.01, Fig. 4, inset). To investigate the
role of CD14, we preincubated PBMC with a neutralizing anti-
CD14 Ab. The anti-CD14 Ab did not influence the production of
cytokines induced by chlamydial Ags (Fig. 4A), whereas it almost
completely blocked the cytokine induction by E. coli LPS (94%
inhibition, p  0.01, Fig. 4, inset). Blockade of the heparan sul-
fate-like glycosaminoglycan chlamydial receptor with heparin was
not able to down-modulate the synthesis of either TNF, IL-1, or
IL-18 (95–117% of control production, p  0.05). Heparan sulfate
alone did not stimulate cytokine production (data not shown).
Stimulation of TNF and IL-1, but not of IL-18, depends on
TLR2
In control experiments, the anti-TLR2 Ab significantly reduced the
TNF production induced by peptidoglycan by 55–70% ( p 0.05).
In contrast, the anti-TLR2 Ab did not influence LPS-induced pro-
duction of TNF (Fig. 4). We confirm earlier data from our group
that blockade of TLR2 by the neutralizing Ab resulted in the re-
duction of proinflammatory cytokine production induced by son-
icated C. pneumoniae: 76% inhibition of TNF production, and
94% inhibition of IL-1 production ( p  0.01, Fig. 4B). In con-
trast, no effect of the anti-TLR2 Ab on the induction of IL-18 could
be demonstrated (7% inhibition, p  0.05, Fig. 4B).
Blocking TLR2, but not TLR4, with specific antagonistic Abs
significantly decreased Chlamydia-induced release of IFN- by
40–65% (from 459  154 to 243  99 pg/ml, p  0.05). This
effect is most likely mediated through initial inhibition of endog-
enous IL-1 release, as90% of IL-1 release was inhibited by the
anti-TLR2 Ab, and IL-1 has proved essential for effective Chlamy-
dia-induced IFN- production (see above).
FIGURE 2. The effect of IL-18BP, anti-IL-12 Abs, TNFBP, and IL-1ra
on C. pneumoniae-stimulated production of IFN-. PBMC were incubated
with C. pneumoniae sonicates in the absence or presence of IL-18BP (125
ng/ml), anti-IL-12 Abs (5 g/ml), TNFBP (10 g/ml), IL-1ra (10 g/ml),
or a combination of IL-18BP and anti-IL-12 Abs. IFN- concentrations
were measured after 48-h stimulation. One hundred percent IFN- produc-
tion represents 353 pg/ml. Donors, n 6; , p 0.05 when compared with
stimulation by Chlamydia sonicate alone; , p  0.01 when compared
with stimulation by Chlamydia sonicate alone.
FIGURE 3. Stimulation of IL-18 production by C. pneumoniae. Human
PBMC were stimulated for 24 h with culture medium, LPS (10 ng/ml),
heat-killed 107 CFU/ml C. albicans or 107 CFU/ml S. aureus, or heat-killed
C. pneumoniae or sonicated Chlamydia at three different concentrations:
103, 104, or 105 IFU/ml. IL-18 concentrations after 24-h incubation time
were measured by ELISA. Donors, n 6; , p 0.01 when compared with
stimulation by conditioned medium.
FIGURE 4. The effect of TLR2, TLR4, and CD14 on C. pneumoniae-
induced stimulation of cytokines in human PBMC. A, Freshly isolated
PBMC were stimulated with C. pneumoniae (). Anti-TLR4 (3) or anti-
CD14 (u) neutralizing Abs (20 g/ml) had no effect on cytokine produc-
tion. B, Freshly isolated PBMC were stimulated with C. pneumoniae ()
and the addition of anti-TLR2 neutralizing Abs (20 g/ml; 3) strongly
diminished TNF and IL-1 production. Inset, The effect of anti-TLR4,
anti-TLR2, or anti-CD14 Abs on TNF production upon stimulation with
LPS (1 ng/ml). Cytokines were measured after 24 h of incubation. Data
represent mean  SEM of six volunteers. , p  0.05.
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Induction of proinflammatory cytokines by C. pneumoniae in
peritoneal macrophages of MyD88/, TLR2/ and TLR4/
mice
Peritoneal macrophages from all the mouse strains tested did not
release detectable proinflammatory cytokines after incubation with
culture medium alone. In addition, peritoneal macrophages iso-
lated from TLR2/ mice produced 60–75% less TNF and IL-1
compared with cells isolated from control TLR2/ (C57BL/6J)
mice ( p  0.05, Fig. 5A), supporting the hypothesis that proin-
flammatory cytokine stimulation by C. pneumoniae is mainly me-
diated by TLR2. In contrast, macrophages isolated from the TLR4-
deficient ScCr mice did not produce detectable cytokines after
stimulation with LPS, but displayed a cytokine production after
stimulation with C. pneumoniae similar to that of control
C57BL/10 mice: 82  10% of control TNF production, and 89 
15% of IL-1 production in controls ( p 0.05, Fig. 5B). C. pneu-
moniae stimulated significantly less IL-18 production in the mu-
rine macrophages of MyD88/, but not TLR2/ and TLR4/
mice (Fig. 5).
The role of de novo protein synthesis for the cytokine induction
by C. pneumoniae
As a recent study has demonstrated that IL-18 release induced by
Chlamydia trachomatis in epithelial cells is independent of de
novo protein synthesis (16), we assessed whether similar mecha-
nisms apply for induction of cytokines by C. pneumoniae. Block-
ade of de novo protein synthesis with cycloheximide has almost
completely blocked the production of TNF and IL-1, whereas the
release of IL-18 induced by C. pneumoniae was not influenced
(Fig. 6). This demonstrates that IL-18 release by C. pneumoniae is
independent of de novo protein synthesis. In contrast, addition of
the ICE inhibitor to the cells stimulated with Chlamydia decreased
the IL-18 production by 35–50% ( p  0.02).
Discussion
In the present study we demonstrate that C. pneumoniae stimulates
production of IFN-, in addition to the proinflammatory cytokines
IL-18, TNF, and IL-1. Endogenous IL-18, IL-12, and IL-1 are
crucial for the induction of IFN-, as the cytokine antagonists IL-
18BP, anti-IL-12 Abs, and IL-1ra strongly reduced IFN- synthe-
sis stimulated by Chlamydia. Whereas stimulation of TNF and
IL-1 synthesis was TLR2 dependent, the release of IL-18 by C.
pneumoniae appeared to be mediated by posttranscriptional mech-
anisms independent of de novo protein synthesis, through TLR2-,
TLR4- and CD14-independent pathways.
Experimental studies have shown that exogenous IFN- pro-
motes plaque development in apoE/ mice (2), whereas the ab-
sence of IFN-R strongly inhibits atherogenesis (3). Our studies
demonstrate that both live C. pneumoniae and acellular chlamydial
components not only induce TNF, IL-1, and IL-6 (19), but are
also a strong stimulus of IFN- production, and this may be a
crucial step in the atherogenic role of Chlamydia. These results are
supported by other studies reporting IFN- production by C. pneu-
moniae infection (20, 21). However, the finding that even acellular
chlamydial components strongly stimulate IFN- production is im-
portant in the view of the reports suggesting that mainly the chla-
mydial Ags and not the live microorganisms are present in the
atheromatous plaques in humans (22, 23). IFN- may induce
atherogenesis by enhancing expression of adhesion molecules and
MHC molecules on vascular cells, and by inhibition of collagen
synthesis by smooth muscle cells (24). Additional atherogenic ef-
fects of C. pneumoniae consist of induction of macrophage foam
cell formation (25, 26), oxidation of low density lipoproteins (27),
induction of transmigration of leukocytes (12), and blockade of
apoptosis of inflammatory cells in the vessel wall (28).
In view of the importance of IFN- for the inflammatory reac-
tions in atherosclerosis, it is important to decipher the regulatory
mechanism responsible for its release. In the context of stimulation
by bacterial components, the monocyte products, IL-18 and IL-12,
are responsible for the IFN- release from T cells (29). This ap-
pears to be true also for stimulation by C. pneumoniae, as the
release of IFN- was strongly down-regulated by the cytokine an-
tagonists IL-18BP and anti-IL-12 Abs. This is in line with the
inhibitory effects of ICE-inhibition on IL-18 release. Similar ef-
fects have been reported for C. trachomatis-induced release of
IFN-, although with this stimulus, the relative role of IL-12 seems
to be more important (16).
FIGURE 5. Stimulation of proinflammatory cytokines by C. pneu-
moniae in MyD88/, and TLR2- and TLR4-deficient mice. Peritoneal
macrophages from MyD88/ and TLR2/ (A) or TLR4/ (B) knock-
out mice were stimulated with C. pneumoniae (105 IFU/ml) for 24 h at
37°C. Cytokine measurement was performed in the supernatants, and the
data represent mean  SEM of seven mice. , p  0.05.
FIGURE 6. Effect of de novo protein synthesis on cytokine stimulation
by C. pneumoniae. Freshly isolated human PBMC were stimulated with
105 IFU/ml C. pneumoniae (), and the effect of de novo protein synthesis
on cytokine stimulation was investigated by adding 10 g/ml cyclohexi-
mide during the stimulation (3). Cytokines were measured in the super-
natant after 24-h incubation at 37°C, and the data represent mean  SEM
of five volunteers. , p  0.05.
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We found that C. pneumoniae was a stronger stimulus for IL-18
production than other microbial components (such as LPS, heat-
killed C. albicans, or S. aureus). From the experiments using IL-
18BP, it can be concluded that the immunoreactive IL-18 is bio-
active. The IL-18 and IFN- production induced by C.
pneumoniae may be very relevant for atherogenesis. First, IL-18
has been shown to be expressed on macrophages in atherosclerotic
plaques (4), its presence has been correlated with an unstable phe-
notype (5), and it has been shown to be a predictor of cardiovas-
cular death in stable and unstable angina (30). Second, gene trans-
fer of a plasmid encoding IL-18BP has been shown to modulate
plaque development and stability (31), whereas administration of
exogenous IL-18 enhanced atherosclerosis in apoE/ mice (32).
Finally, it is important to note that these effects of IL-18 are de-
pendent on IFN- release (32).
In our experiments, endogenous IL-1 was involved in the reg-
ulation of IFN- synthesis, as IL-1ra also strongly decreased Chla-
mydia-induced IFN- production, although in earlier studies, IL-
1ra failed to show significant inhibitory activity (19). Although
IL-1 by itself cannot stimulate production of IFN-, recent data
indicate that addition of IL-1 to IL-12 potentiates the induction of
IFN- (33). Our results are supported by Hunter et al. (34), who
reported inhibition of IFN- by anti-IL-1 Abs when stimulation
was induced by microbial stimuli such as LPS, heat-killed Toxo-
plasma gondii, Salmonella typhimurium, Legionella pneumophila,
and Yersinia pseudotuberculosis. This role of IL-1 may be ex-
plained by structure similarities between the receptor complexes
for IL-1 and IL-18, which consist of a binding chain (IL-1R type
I and IL-18R) and a signaling chain (IL-1R accessory protein and
IL-18R) respectively (29). In addition to IL-18, IL-12, and IL-1,
Rothfuchs and colleagues (35) have also suggested IFN- medi-
ated induction of IFN- by C. pneumoniae infection of bone mar-
row-derived macrophages, and this mechanism may also be
present in our system.
A second aim of the present study was to investigate the mech-
anisms responsible for the stimulation of proinflammatory cyto-
kines by C. pneumoniae. TLRs are pattern-recognition receptors
believed to have a central role in the innate immunity to pathogens.
Ten human TLRs have been identified to date, some of which have
crucial roles in the recognition of pathogen-associated molecular
patterns, such as TLR4 for LPS and lipoteichoic acid, TLR2 for
peptidoglycans, lipoarabinomannan and bacterial lipoproteins,
TLR5 for flagellin, and TLR9 for bacterial DNA (for review see
Ref. 36). As we and others have previously shown, C. pneumoniae
uses TLR2 as signaling receptor to induce production of TNF and
IL-1 (37, 38), and we now further substantiated these findings in
mice deficient in TLR2 or TLR4. In addition, C. pneumoniae in-
duced IFN- through TLR2-dependent mechanisms, a process in
which down-regulation of endogenous IL-1 is likely to be in-
volved. The lack of effect of TLR4 on induction of cytokines by
Chlamydia is also in line with the fact that heat-killed Chlamydia
was much less potent for the stimulation of proinflammatory cy-
tokines, suggesting that not (heat-stable) chlamydial LPS, but a
heat-labile component is responsible for the stimulatory activity
(19).
An important new finding is that induction of IL-18 by C. pneu-
moniae appears to be mediated by a different pathway, because its
production is influenced by neither anti-TLR2, nor anti-
TLR4-blocking Abs. Blockade of CD14 also did not influence the
production of any of the cytokines studied. The lack of effects of
the anti-TLR2 and anti-TLR4 Abs could have been due to a dif-
ferent binding site of the putative TLR agonists of C. pneumoniae.
However, the similar lack of effects on cytokine production in the
absence of TLRs in the knockout mice demonstrate that neither
TLR2, nor TLR4, are involved in Chlamydia-induced IL-18. In
contrast to TLR2/ and TLR4/ mice, macrophages of
MyD88/ mice produced significantly less IL-18 than control
macrophages, suggesting that other TLR pathways mediate the re-
lease of IL-18 by C. pneumoniae. Further studies are warranted to
determine what pathways play a role here.
The differential pathways used to stimulate TNF and IL-1 on
the one hand, and IL-18 on the other hand, do not appear to be a
phenomenon restricted to Chlamydia stimulation. Whereas TNF
and IL-1 induction mainly involves transcription, the blockade of
IL-18 release by an ICE inhibitor demonstrates the crucial role of
processing mechanisms in the release of IL-18 by C. pneumoniae.
This is in line with a recent study, in which Lu and colleagues (16)
have shown the release of mature IL-18 from epithelial cells in-
fected with C. trachomatis, independent of de novo protein syn-
thesis. This release was mediated by posttranscriptional mecha-
nisms dependent on activation of caspase-1 and cleavage of
inactive pro-IL-18 into active mature IL-18. Similarly, in our ex-
periments, C. pneumoniae-induced production of TNF and IL-1
was completely dependent on transcriptional mechanisms and de
novo protein synthesis, whereas the blockade of protein synthesis
by cycloheximide did not influence IL-18 release. This suggests
that IL-18 release induced by both C. pneumoniae and C. tracho-
matis is mediated by similar posttranscriptional events indepen-
dent of de novo protein synthesis. The precise receptors through
which Chlamydia induces the release of IL-18 are currently un-
known, but recognition of chlamydial components by TLR other
than TLR2 and TLR4, 1,2 integrins, (39) or heparan sulfate-like
glycosaminoglycans (15) may be involved. The role of the latter
seems to be excluded by the lack of effect of heparin in our
experiments.
In conclusion, C. pneumoniae is a potent stimulus of IL-18/
IFN- production, in addition to the proinflammatory cytokines
TNF and IL-1, which may contribute to its proatherogenic ef-
fects. Interestingly, C. pneumoniae induces TNF and IL-1 syn-
thesis through TLR2-mediated signals, whereas stimulation of
IL-18 production is mediated through pathways independent of
TLR2 and TLR4.
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